Pancreatic Cancer: Byetta / Victoza / Januvia / Janumet / Byedureon
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Incretin diabetes drugs – pancreatic cancer lawsuits are being filed against the responsible pharmaceutical companies due to their failure to warn patients about this serious side effect.
Here is a list of incretin diabetes drugs currently approved by the FDA:
- Byetta (exenatide)
- Bydureon (exenatide)
- Victoza (liraglutide)
- Januvia (sitagliptin)
- Janumet (sitagliptin)
- Janumet XR (sitagliptin)
- Juvisync (sitagliptin)
- Onglyza (saxagliptin)
- Kombiglyze XR (saxagliptin)
- Nesina (alogliptin)
- Kazano (alogliptin)
- Oseni (alogliptin)
- Tradjenta (linagliptin)
- Jentadueto (linagliptin)
Our law firm is investigating incretin diabetes drugs lawsuits for personal injury or wrongful death cases that involve Pancreatic Cancer, also known as Pancreas Cancer.
NOTE: We are no longer taking cases involving:
- Pancreatitis
- Thyroid Cancer
- Kidney Failure
Free Incretin Diabetes Drugs Case Evaluation
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
Current Number Of Lawsuits Filed In Diabetes Drugs Federal Court MDL Cases
From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases for diabetes drugs.
To read more of this article, click below:
1) IN RE: Incretin-Based Therapies Products Liability Litigation
Number of lawsuits pending in MDL-2452: 936
Primary side effect for these cases:
Pancreatic Cancer / Pancreas Cancer
2) IN RE: Invokana (Canagliflozin) Products Liability Litigation
Number of lawsuits pending in MDL-2750: 985
Primary side effects for these cases:
Diabetic Ketoacidosis (DKA)
Leg Amputation / Foot or Toe(s) Amputation
3) IN RE: Farxiga (Dapagliflozin) Products Liability Litigation
Number of lawsuits pending in MDL-2776: 51
Primary side effect for these cases:
Diabetic Ketoacidosis (DKA)
4) IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability Litigation
Number of lawsuits pending in MDL-2809: 84
Primary side effect for these cases:
Heart Failure
We will continue to monitor the number of pending lawsuits in these four distinct diabetes drugs MDL cases and watch for significant developments in each of these federal court MDL litigations.
[Read article in full at original source]Earlier articles by attorney Tom Lamb on the Drug Injury Watch blog:
- Pancreatic Cancer Lawsuits Reinstated for Incretin-Based Diabetes Drugs
- Diabetes Drugs Bydureon And Victoza: Thyroid Cancer Label Change In March 2015 Comes Without Much Notice
- Pancreatic Cancer As A Side Effect Of Diabetes Drugs Bydureon, Byetta, Januvia, And Victoza
- Byetta / Januvia / Victoza: Update On Possible Association Between These Newer Diabetes Drugs And Pancreatic Cancer As A Side Effect
- Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza?
- Emerging Drug Safety Issue: Possible Increased Risk Of Pancreatic Cancer With Byetta, Januvia, And Victoza — Little Is Known About Long-Term Effects
- Byetta And Januvia: More Debate About The Possible Increased Risk Of Pancreatitis, Pancreatic Cancer, And Thyroid Cancer
- Gastroenterology Medical Journal Withdraws Januvia / Byetta Article Due To Letters From Drug Companies
- FDA Wants Studies Done On Byetta Safety, With Focus On Pancreatitis, Pancreatic Cancer, Thyroid Neoplasm, And Acute Renal Failure
Free Case Evaluation: Incretin Diabetes Drugs >>
All content by attorney Tom Lamb